Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trifarotene (Primary)
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Acronyms PERFECT 2
  • Sponsors Galderma

Most Recent Events

  • 21 Mar 2023 Results of Pooled Post-hoc analysis , from PERFECT 1 and PERFECT 2 of Safety and Efficacy of Trifarotene 0.005 percent Cream Within the Adolescent Population, presented at the American Academy of Dermatology annual Meeting 2023
  • 07 Apr 2020 Results from PERFECT 1 and PERFECT 2 and NCT02189629 assessing safety and efficacy published in the JAMA: the Journal of the American Medical Association
  • 08 Jan 2020 According to a Galderma media release, Certara's Simcyp based Simulator was used to support U.S. Food and Drug Administration (FDA) new drug application (NDA) for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top